Generation Bio Co.

Equities

GBIO

US37148K1007

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
2.9 ^USD	-3.65%		+3.57%	+75.76%

Apr. 12	Transcript : Generation Bio Co. - Special Call
Mar. 07	Needham Cuts Price Target on Generation Bio to $10 From $14, Maintains Buy Rating	MT

Generation Bio Co. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023

November 09, 2023 at 04:26 pm EST

Generation Bio Co. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net loss was USD 28.27 million compared to USD 31.31 million a year ago. Basic loss per share from continuing operations was USD 0.43 compared to USD 0.53 a year ago.
For the nine months, net loss was USD 91.43 million compared to USD 104.23 million a year ago. Basic loss per share from continuing operations was USD 1.43 compared to USD 1.81 a year ago.

Latest news about Generation Bio Co.

Transcript : Generation Bio Co. - Special Call	Apr. 12
Needham Cuts Price Target on Generation Bio to $10 From $14, Maintains Buy Rating	Mar. 07	MT
Generation Bio Co. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 06	CI
Generation Bio Co. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 06	CI
Transcript : Generation Bio Co. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 09:10 AM	Mar. 05
Generation Bio Co.(NasdaqGS:GBIO) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
Generation Bio Insider Bought Shares Worth $124,778, According to a Recent SEC Filing	Dec. 05	MT
Wedbush Adjusts Generation Bio Price Target to $5 From $9, Maintains Outperform Rating	Nov. 29	MT
Generation Bio to Lay Off 40% of Staff in Bid to Extend Cash Runway Into H2 2027	Nov. 29	MT
Generation Bio Co. Announces Termination of Executives, Effective on January 28, 2024	Nov. 29	CI
Wedbush Lowers Generation Bio's Price Target to $9 From $11, Maintains Outperform Rating	Nov. 10	MT
Generation Bio Co. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Generation Bio Co. Announces Demonstration of Highly Selective T Cell Transduction in Vivo with Cell-Targeted Lnp Platform	23-10-26	CI
North American Morning Briefing : Yields Fall -2-	23-10-24	DJ
JMP Securities Downgrades Generation Bio to Market Perform From Market Outperform	23-10-23	MT
North American Morning Briefing : Bond Yields, -2-	23-10-20	DJ
TD Cowen Downgrades Generation Bio to Market Perform From Outperform	23-10-19	MT
Generation Bio Co. Announces Breakthrough in Its Non-Viral Genetic Medicine Platform with Novel "Immune-Quiet" Dna	23-10-18	CI
Generation Bio Sank 10% in After-Hours Thursday, Setting Stage for Fourth Straight Day of Losses in Regular Trading Friday	23-09-08	MT
JPMorgan Chase Adjusts Price Target on Generation Bio to $9 From $8, Maintains Neutral Rating	23-08-16	MT
Generation Bio Co. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-02	CI
Generation Bio Co. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Generation Bio Co., Appoints Yalonda Howze, J.D., as Chief Legal Officer and Secretary	23-04-05	CI
Sector Update: Health Care Stocks Mixed During Late Afternoon	23-03-23	MT
Wedbush Cuts Generation Bio's Price Target to $11 From $15, Maintains Outperform Rating	23-03-23	MT

Chart Generation Bio Co.

Duration

Period

More charts

Company Profile

Generation Bio Co. is a biotechnology company. The Company is innovating non-viral genetic medicines to provide durable, redosable treatments for hundreds of millions of patients living with rare and prevalent diseases. The Company is developing two distinct and complementary platforms: a potent, highly selective cell-targeted lipid nanoparticle (ctLNP) delivery system and a novel immune-quiet DNA (iqDNA) cargo produced by a scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis (RES). The Company is advancing a portfolio of programs guided by the potent and highly selective delivery of messenger ribonucleic acid (mRNA) and/or iqDNA using its ctLNP delivery system to target T cells, hematopoietic stem cells (HSCs), and hepatocytes, and intend to expand to additional tissues and cell types. Its work in T cells focuses on in vivo reprogramming of this cell type to treat cancer and autoimmune diseases.

Sector

Biotechnology & Medical Research

Calendar

2024-05-01 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Generation Bio Co.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.9 USD

Average target price

7.5 USD

Spread / Average Target

+158.62%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
GENERATION BIO CO.	+75.76%	193M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs